Alpha Tau Medical Ltd. (NASDAQ: DRTS) announced that an abstract combining pancreatic cancer data from three clinical studies has been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 through June 2, 2026.

The abstract, titled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer," presents pooled analysis of safety and efficacy data from 58 patients across three studies conducted at centers in Canada and Israel.

The studies evaluated endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. The research was conducted at Jewish General Hospital and Centre Hospitalier de l'Université de Montréal in Canada, and Hadassah Medical Center in Israel.

The abstract will be published on the ASCO conference website on May 21, 2026, at 5:00 PM ET. Alpha Tau previously presented pancreatic cancer data at the ASCO Gastrointestinal Cancers Symposium and Digestive Disease Week earlier this year.

Alpha DaRT is designed as an intratumoral radiation therapy that uses alpha-emitting sources inserted directly into tumors to release therapeutic particles intended to destroy cancer tissue while minimizing damage to surrounding healthy tissue.

The company currently operates two additional pancreatic cancer trials: the IMPACT trial in the United States evaluating Alpha DaRT combined with chemotherapy in newly diagnosed unresectable pancreatic cancer, and the ACAPELLA trial in France studying Alpha DaRT with capecitabine in locally advanced pancreatic cancer patients.